Inclusion Criteria:

- Histologically confirmed, advanced HPV-positive cervical, vulvar, vaginal, penile,
anal or head and neck cancer cancers under progression, regression or with stable
disease after standard therapy (and still incurable) or after refusal of standard
therapy or with contraindications for standard treatment

- HPV positivity as tested by HPV genotyping from paraffin embedded tumor tissue

- Diffuse expression of p16INK4a in the tumor as analyzed by immunohistochemistry on
paraffin embedded tumor tissue.

- Expected survival of at least six months.

- Full recovery from surgery, chemo therapy or radiation therapy.

- ECOG performance status 0, 1 or 2.

- The following laboratory results:

Neutrophil count ≥ 1.5 x 109/L Lymphocyte count ≥ 0.5 x 109/L Platelet count ≥ 100 x 109/L
Serum bilirubin < 2mg/dL

- Male or female patients ≥ 18 years old

- Patient´s written informed consent for participation in the trial

Exclusion Criteria:

- Prior treatment with P16_37-63 peptide

- Clinically significant heart disease (NYHA Class III or IV).

- Other serious illnesses, eg, serious infections requiring antibiotics or bleeding
disorders.

- History of immunodeficiency disease or autoimmune disease.

- Metastatic disease to the central nervous system for which other therapeutic options,
including radiotherapy, may be available.

- HBV, HCV or HIV positivity.

- Chemotherapy, any type of radiation therapy, or immunotherapy within 4 weeks before
study entry

- Concomitant treatment with steroids, antihistaminic drugs, or nonsteroidal
anti-inflammatory drugs (unless used in low doses for prevention of an acute
cardiovascular event or for pain control). Topical or inhalational steroids are
permitted.

- Participation in any other clinical trial involving another investigational agent
within 4 weeks.

- Pregnancy or lactation.

- Women of childbearing potential who are not using a medically acceptable means of
contraception.

- Psychiatric or addictive disorders that may compromise the ability to give informed
consent.

- Lack of availability of a patient for immunological and clinical follow-up
assessment.

- Brain metastases (symptomatic and non-symptomatic)